Could a hormone made famous by Ozempic secretly help defend your brain against Alzheimer’s disease? New research says… maybe.
In this letter, we’re going to unravel this science. Here’s our roadmap:
The Unexpected Link: First, we’ll walk through the new data showing the inverse relationship between GLP-1 hormone and the amyloid plaques seen in Alzheimer's disease.
Decoding the "How": Next, I'll break down the elegant biological mechanism the researchers uncovered—exactly how GLP-1 signaling puts the brakes on the brain's amyloid production line.
Action Steps and Questions: Finally, I’ll share five actionable, science-backed strategies you can use to support this specific pathway for better brain metabolism. Plus I'll explore my top four pressing questions that this new research raises for the future of Alzheimer's prevention.
Inverse relationship: GLP-1 vs Brain Amyloid
Look at the graph and brain images below. Let’s start with the graph, which represents the relationship between levels of the hormone GLP-1 circulating in the blood and levels of amyloid in the human brain. GLP-1 is the now-famous weight loss hormone that drugs like Ozempic and Wegovy mimic, and amyloid is a hallmark of Alzheimer’s disease.
Clearly, there’s an inverse relationship: Lower GLP-1 levels associate with more amyloid; higher GLP-1 levels associate with less amyloid.
The brain images reinforce the point:
More yellow and red tones indicate more amyloid
More green and blue tones suggest less amyloid.
The brain on the left is the scan from the patient with the lowest GLP-1 levels of the twelve represented in the graph; the brain on the right is the scan from the patient with the highest GLP-1 level.
There’s unmistakably an antagonistic relationship between GLP-1 levels and amyloid. Let’s delve into new data to explain why this pattern exists — and what it might mean for your brain health.
The New Paper that Piqued my Curiosity
These data come from a new paper in Nature Aging, in which researchers set out to study the mechanism by which GLP-1 receptor agonist (GLP-1RA) medications like Ozempic and Wegovy — as well as newer-generation combination agonists like Tirzepatide — might protect against Alzheimer’s disease.
There are already promising signals in the data, including results from a large Danish registry-based cohort study in 120,054 patients with diabetes showing 11% lower rates of dementia among those treated with GLP-1Ras. This is consistent with data from other randomized trials targeting cardiovascular outcomes, and a 12-month Phase II randomized trial in adults with mild cognitive impairment. But the evidence is still early, and the mechanism murky.
So, the researchers asked — in very technical terms — “What’s up doc?”
Unraveling the Mechanism
After observing an inverse association between GLP-1 and amyloid levels in both humans with Alzheimer’s disease and a mouse model of the disease, they conducted a set of carefully controlled mechanistic experiments that decoded the following pathway:
They uncovered the biological pathway:
GLP-1 (blue, below) binds to receptors in the brain.
This flips on a crucial metabolic switch called AMPK (purple, below) .
AMPK then shuts down a pro-inflammatory complex called NFkB, reducing inflammation in the brain (to the left of the middle AMPK).
With inflammation down, the brain’s immune cells — called microglia — become better at gobbling up amyloid and clearing debris (left, orange rectangle).
Most importantly, AMPK suppresses an enzyme called BACE1 — the enzyme that starts the whole amyloid production process (pink, below). BACE1 is critical in making the amyloid oligomers that mark — and are thought to contribute to — the pathological cascade of Alzheimer’s disease. Specifically, BACE1 is the enzyme that initially chops the amyloid precursor protein (APP) into a form that then undergoes subsequent processing into neurotoxic Aβ40 and Aβ42 oligomers.
Keep It Simple Stupid: Amyloid Cupcakes
I wanted to show you the summative figure from the paper. But I realize it’s intimidating, so here’s the simple version:
GLP-1RAs decrease neuroinflammation
GLP-1RAs improve amyloid clearance
GLP-1RAs decrease amyloid production by inhibiting BACE1
If toxic amyloid were cupcakes, BACE1 is the cupcake tin. Without BACE1, there are no amyloid cupcakes.
In the rest of this letter, we will discuss:
How this Actually Impacts Brain Health
My Top 4 Pressing Questions from the research
5 Actionable Tools you can implement Today to improve brain metabolism
